November 30, 2015
Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

Type 2 diabet"...




There were no reports of overdose during the clinical development program of INVOKANA (canagliflozin).

In the event of an overdose, contact the Poison Control Center. It is also reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment as dictated by the patient's clinical status. Canagliflozin was negligibly removed during a 4-hour hemodialysis session. Canagliflozin is not expected to be dialyzable by peritoneal dialysis.


History of a serious hypersensitivity reaction to INVOKANA [see WARNINGS AND PRECAUTIONS].

Severe renal impairment (eGFR less than 30 mL/min/1.73 m²), end stage renal disease (ESRD), or patients on dialysis [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 9/23/2015


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.